Yumi Fujimoto

Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells

Yumi Fujimoto, Tomoko Morita, Akihiro Ohashi et al. · Scientific Reports · 2020 · 85 citations · Full text

Clinical practice guidance for next‐generation sequencing in cancer diagnosis and treatment (Edition 1.0)

Kuniko Sunami, Hideaki Takahashi, Katsuya Tsuchihara et al. · Cancer Science · 2018 · 57 citations · Full text

X-Ray Crystal Structures of Octahedral Diaquabis(<i>N</i>,<i>N</i>-dialkyl-ethylenediamine)nickel(II) Complexes Possessing Elongated Nickel(II)–Nitrogen Bonds along Axial Direction

Yoshinori Ihara, Yasuhiro Satake, Yumi Fujimoto et al. · Bulletin of the Chemical Society of Japan · 1991 · 17 citations

Materials Science, Inorganic Chemistry, X-ray Crystallographic Studies +15

Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up

Takashi Kobayashi, Naoki Terada, Takahiro Kimura et al. · Clinical Genitourinary Cancer · 2019 · 13 citations

Urology, Oncology, Sequential Use +8